Ask Warren

Enzychem Lifesciences

183490 · KOSDAQ · ₩183490 · 엔지켐생명과학

₩990 ₩0 (0.00%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩24B₩15B₩14B₩16B₩16B₩21B₩19B₩17B
Cost of sales₩21B₩15B₩14B₩16B₩16B₩19B₩18B₩16B
Gross profit₩2B₩344M₩552M₩435M₩801M₩1.6B₩298M₩887M
Operating income−₩4.1B−₩3.2B−₩4.4B−₩3.7B−₩3.7B−₩2.6B−₩4.7B−₩2.7B
Net income−₩864M−₩1.9B−₩15B−₩278M−₩1.2B−₩1.8B−₩20B₩1.7B
Net income to shareholders−₩2.9B−₩1.9B−₩9.9B−₩3.3B−₩3.1B−₩1.9B−₩16B−₩1.6B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩168B₩161B₩149B₩168B₩172B₩177B₩182B₩189B
Current assets₩136B₩129B₩116B₩137B₩140B₩143B₩148B₩156B
Cash and equivalents₩25B₩14B₩7.8B₩11B₩13B₩11B₩10B₩6.8B
Total liabilities₩19B₩11B₩9.8B₩18B₩17B₩19B₩20B₩11B
Current liabilities₩10B₩9.5B₩8.2B₩7.8B₩8.1B₩9.4B₩11B₩8.8B
Borrowings₩11B₩5.1B₩4.2B₩3.8B₩3.6B₩3.6B₩3.8B₩3.7B
Total equity₩149B₩150B₩139B₩150B₩154B₩158B₩161B₩179B
Shareholders' equity₩146B₩149B₩138B₩149B₩153B₩156B₩160B₩178B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations−₩6.8B−₩2.8B−₩8.5B−₩1.1B₩1.8B−₩3.2B₩632M₩1.9B
Free cash flow−₩6.8B−₩2.8B−₩8.5B−₩1.1B₩1.8B−₩3.2B₩632M₩1.9B

Consolidated where available. Amounts in won.

Also known as: Enzychem Lifesciences / 엔지켐생명과학 / 183490 / KRX:183490

Source: KRX statistical information